Loading stock data…
$12.89-0.02 (-0.15%)
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States.
Crescent Biopharma, Inc. in the Healthcare sector is trading at $12.89 with a market capitalization of $637M. Wall Street consensus targets $31.50 (6 analysts), implying a +144.4% move over the next 12 months. The stock is currently 53% below its 52-week high of $27.41, remaining 18.4% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $1.04M↓ | $10.84M | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.36M↓ | -$24.73M↑ | -$91.49M↓ | -$25.89M↓ | -$21.03M |
| Net Income | -$24.84M↓ | -$23.28M↑ | -$92.40M↓ | -$24.61M↓ | -$21.79M |
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to trea...